Clinical Trials List
Protocol NumberGO46057
Not yet recruiting
2026-01-01 - 2030-12-31
Phase I
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wei-Wu Chen Division of Hematology & Oncology
- 李佳真 Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
- 楊明翰 Division of Hematology & Oncology
- 羅 喬 Division of General Surgery
- WEI-LI MA Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- 林柏翰 Division of General Internal Medicine
- 林季宏 Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
Co-Principal Investigator
- Kuo-Ting Lee Division of General Surgery
- Chun-Hui Lee Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
- 魏慈慧 Division of General Surgery
- Shang-Hung Chen Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- 黃怡菁 Division of Hematology & Oncology
- Zhu-Jun Loh Division of General Surgery
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
32-136 participants
